Showing all 5 results
NGS Colorectal Cancer Panel Test – Comprehensive Genetic Profiling for Precision Oncology The NGS Colorectal Cancer Panel Test from Lab Tests Dubai is a cutting-edge, next-generation sequencing (NGS) diagnostic tool that analyzes the genetic makeup of colorectal tumors to guide precision treatment, predict drug response, and identify hereditary cancer syndromes like Lynch syndrome. This advanced…
The **Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 Literature-Reviewed Genes** is a comprehensive genetic test designed to assess hereditary cancer risk. It analyzes **57 key genes**, including the **ACMG 20** and **HBOC-related genes**, alongside **865 literature-reviewed genes**, ensuring a thorough evaluation of cancer predisposition. This panel covers a wide range of hereditary cancers, including **breast, ovarian, colorectal, and more**, providing **clinically actionable insights** for early detection and personalized risk management. Utilizing **advanced sequencing technology**, it delivers **high accuracy and reliability**, making it an essential tool for **patients, healthcare providers, and genetic counselors**. Its unique combination of **expert-curated genes and extensive literature review** enhances diagnostic precision, setting it apart as a **cutting-edge solution for hereditary cancer risk assessment**.
Liquid HALLMARK is a comprehensive liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a simple blood draw to detect and monitor cancer.
Sample Type : Serum
Methodology : Ultra-deep sequencing using Lucence’s proprietary AmpliMARK™ technology
TAT : 8-10 Days
The Oncomine Acute Myeloid Leukaemia (AML) Panel is a targeted next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of AML. It enables simultaneous detection of key mutations, gene fusions, and copy number variations across clinically relevant genes associated with AML.
The Oncomine Comprehensive Myeloid/Leukemia Panel (DNA + RNA fusions) is a next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of myeloid malignancies and leukemias. It simultaneously analyzes DNA and RNA to detect key mutations, copy number variations, and gene fusions across a broad range of clinically relevant genes.
